Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(3 sites)

United States

Raj K. Maturi, M.D., P.C., Carmel, Indiana

Retina Research Institute of Texas, Abilene, Texas

Strategic Clinical Research Group LLC, Willow Park, Texas